진매트릭스
Financials
Valuation Metrics
진매트릭스's Market Cap is ₩286B. At end of 2025 it was ₩501B. Ranked #2057 of 2,410 in KR market (top 85%), #1311 of 1,631 on KOSDAQ (top 80%), #215 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 93%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 28.55B KRW | KR#2,057/2,410 Sec#215/231 |
| Revenue | 10.88B KRW | KR#2,271/2,410 Sec#173/231 |
| Net Income | -189.9M KRW | KR—/2,410 Sec—/231 |
| Total Assets | 27.59B KRW | KR#2,343/2,410 Sec#223/231 |
| Net Assets | 17.94B KRW | KR#2,309/2,410 Sec#217/231 |
| Employees | 67 | KR#1,909/2,410 Sec#167/231 |
| Value | ||
| P/B | 1.59x | KR#1,871/2,410 Sec#137/231 |
| P/S | 2.62x | KR#1,977/2,410 Sec#119/231 |
| FCF Yield | 4.29% | KR#930/2,410 Sec#56/231 |
| Profitability | ||
| ROE | -1.06% | KR#1,625/2,410 Sec#111/231 |
| ROA | -0.69% | KR#1,636/2,410 Sec#111/231 |
| Op. Margin | -2.15% | KR#1,745/2,410 Sec#118/231 |
| Revenue Growth | 4.17% | KR#1,245/2,410 Sec#126/231 |
| Financial Health | ||
| Debt Ratio | 53.83% | KR#1,012/2,410 Sec#118/231 |
| Total Debt | 3.60B KRW | KR#1,833/2,410 Sec#178/231 |
| FCF | 1.23B KRW | KR#1,133/2,410 Sec#82/231 |
| Cash | 5.66B KRW | KR#1,964/2,410 Sec#180/231 |
| Current Ratio | 4.77x | KR#304/2,410 Sec#52/231 |
| Performance | ||
| 1Y Return | -43.32% | KR#1,766/2,410 Sec#150/231 |
| 1M Return | -8.50% | KR#942/2,410 Sec#95/231 |
| From 52W High | -49.91% | KR#1,094/2,410 Sec#84/231 |
| 1Y MDD | -48.37% | KR#888/2,410 Sec#70/231 |
| Trading | ||
| Volume | 18,059 shares | KR#1,364/2,410 Sec#138/231 |
| Trading Value | 25.2M KRW | KR#1,842/2,410 Sec#193/231 |
| Foreign Own. | 1.57% | KR#1,800/2,410 Sec#177/231 |
| Per Share | ||
| EPS | -9 KRW | KR—/2,410 Sec—/231 |
| BPS | 880 KRW | KR#2,322/2,410 Sec#215/231 |
Company Info
Genematrix, established in 2000 and headquartered in Seongnam-si, Gyeonggi-do, was founded to develop pharmaceuticals and diagnostics using biotechnology, listing on KOSDAQ in 2009. The company develops and sells medical diagnostic reagents, including molecular diagnostics and biochemical reagents, leveraging its proprietary technologies. It is also developing vaccines and immuno-oncology therapeutics for disease prevention and treatment. Genematrix possesses multiplex testing technology through key products for diagnosing sexually transmitted infections, tuberculosis, and human papillomavirus, facilitating its expansion into global markets.